The present invention relates to an adjuvant composition and a vaccine composition, each comprising a STING agonist. The adjuvant composition and the vaccine composition according to the present invention, which each comprise a STING agonist, are identified not only to have the ability to effectively activate various immune responses within the body, but also to exhibit the effect of significantly reducing the infection caused by causative agents of tuberculosis. Thus, when used in combination of vaccines against other pathogens, the compositions are expected to effectively reduce infection caused by various pathogens as well as causative agents of tuberculosis by remarkably augmenting effects of the conventional vaccines for preventing infection.La présente invention concerne une composition d'adjuvant et une composition de vaccin, comprenant chacune un agoniste de STING. La composition d'adjuvant et la composition de vaccin selon la présente invention, qui comprennent chacune un agoniste de STING, sont identifiées non seulement pour avoir la capacité d'activer efficacement diverses réponses immunitaires à l'intérieur de l'organisme, mais également pour avoir pour effet de réduire significativement l'infection provoquée par les agents responsables de la tuberculose. Ainsi, lorsqu'elles sont utilisées dans des combinaisons de vaccins contre d'autres agents pathogènes, on s'attend à ce que ces compositions réduisent efficacement l'infection provoquée par divers agents pathogènes, ainsi que par les agents responsables de la tuberculose en renforçant considérablement les effets des vaccins classiques pour prévenir l'infection.본 발명은 STING 작용자를 포함하는 면역항원보강제 조성물 및 백신 조성물에 관한 것으로, 본 발명에 따른 STING 작용자를 포함하는 면역항원보강제 조성물 및 백신 조성물은 다양한 체내 면역 반응을 효과적으로 활성화시킬 수 있을 뿐만 아니라, 결핵균의 감염을 현저히 감소시키는 효과를 확인하였기 때문에, 결핵균뿐만 아니라 다른 병원균들의 백신과 함께 사용하면 기존의 감염 예방용 백신 효과를 현저히 증가시켜 다양한 병원균의 감염을 효과적으로 감소시킬 수 있을 것으로 기대된다.
